Jane Street Group LLC Cuts Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Jane Street Group LLC lowered its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 84.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,813 shares of the life sciences company's stock after selling 327,044 shares during the period. Jane Street Group LLC owned about 0.08% of Integra LifeSciences worth $1,105,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Systematic Financial Management LP lifted its position in Integra LifeSciences by 53.9% in the 3rd quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company's stock worth $11,115,000 after buying an additional 214,272 shares during the last quarter. Sachem Head Capital Management LP bought a new stake in shares of Integra LifeSciences in the 3rd quarter worth approximately $44,153,000. Centiva Capital LP purchased a new stake in shares of Integra LifeSciences in the 3rd quarter valued at $192,000. Clearline Capital LP grew its holdings in shares of Integra LifeSciences by 226.8% during the 3rd quarter. Clearline Capital LP now owns 230,397 shares of the life sciences company's stock valued at $4,186,000 after purchasing an additional 159,903 shares during the last quarter. Finally, Walleye Capital LLC raised its position in Integra LifeSciences by 758.7% in the 3rd quarter. Walleye Capital LLC now owns 234,506 shares of the life sciences company's stock worth $4,261,000 after purchasing an additional 207,196 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of recent research reports. BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. Citigroup raised their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, October 14th. Bank of America dropped their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research report on Monday, October 7th. Finally, Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price objective on the stock. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences has an average rating of "Hold" and a consensus target price of $23.00.

Integra LifeSciences Trading Up 0.6 %

NASDAQ IART traded up $0.14 during trading on Monday, hitting $22.47. The company had a trading volume of 434,653 shares, compared to its average volume of 636,038. The company's fifty day moving average is $22.80 and its 200-day moving average is $23.10. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same period in the prior year, the firm earned $0.76 earnings per share. Integra LifeSciences's revenue was down .4% on a year-over-year basis. Equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.